Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure

Experimental and Clinical Cardiology

Volumn 15, Issue 4, 2010, Pages

  Rehsia, Navneet S ^a,b   Dhalla, Naranjan S ^a,b  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

adrenoceptor antagonists; Atenolol; Carvedilol; Heart failure; Metoprolol; Propranolol

Indexed keywords

ADRENALIN; ATENOLOL; BETAXOLOL; BISOPROLOL; BUCINDOLOL; BUTOXAMINE; CALCIUM CHANNEL; CALMODULIN; CARTEOLOL; CARVEDILOL; CATECHOLAMINE; CYCLIC AMP; DOXAZOSIN; ESMOLOL; IVABRADINE; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PHENOXYBENZAMINE; PHENTOLAMINE; PLACEBO; PRAZOSIN; PROPRANOLOL; RYANODINE; TAMSULOSIN; TIMOLOL; YOHIMBINE;

ADRENALIN BLOOD LEVEL; APOPTOSIS; CATECHOLAMINE BLOOD LEVEL; CONGESTIVE HEART FAILURE; DIZZINESS; DRUG MECHANISM; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HUMAN; HYPOTENSION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 79952567687     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Dhalla NS, Wang X, Sethi R, Das PK, Beamish RE. β-adrenergic linked signal transduction mechanisms in failing hearts. Heart Fail Rev 1997;2:55-65. (Pubitemid 28231108)
2. Gheorghiade M, Benatar D, Konstam MA, Stoukides CA, Bonow RO. Pharmacotherapy for systolic dysfunction: A review of randomized clinical trials. Am J Cardiol 1997;80:14-27.
3. Frishman WH. Beta-adrenergic blockers: A 50-year historical perspective. Am J Therap 2008;15:565-76.
4. Spann JF, Sonnenblick EH, Cooper T, Chidsey CA, Willman VL, Braunwald E. Cardiac norepinephrine stores and the contractile state of heart muscle. Circ Res 1966;19:317-25.
5. Swedberg K, Viquerat C, Rouleau JL, et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984;54:783-6. (Pubitemid 14006148)
6. Adameova A, Abdellatif Y, Dhalla NS. Role of excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol 2009;87:493-514.
7. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26-40.
8. 2 subunit of L-type voltage-dependent calcium channels. Biochemistry 1999;10:10361-70.
9. Castellano M, Bohm M. The cardiac β-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997;29:715-22. (Pubitemid 27097975)
10. Opie L. Receptors and signal transduction. In: Opie L, ed. The Heart: Physiology, from Cell to Circulation. Philadelphia: Lippincott, Williams and Wilkins, 2001:173-207.
11. 2+/calmodulin kinase II. J Clin Invest 2003;111:617-25.
12. Olofsson MH, Havelka AM, Brnjic S, Shoshan MC, Linder S. Charting calcium-regulated apoptosis pathways using chemical biology: Role of calmodulin kinase II. BMC Chem Biol 2008;8:2.
13. Leicht M, Greipel N, Zimmer H. Comitogenic effect of catecholamines on rat cardiac fibroblasts in culture. Cardiovasc Res 2000;48:274-84.
14. 2 adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res 2003;57:784-92.
15. Communal C, Colucci WS. The control of cardiomyocyte apoptosis via the beta-adrenergic signaling pathways. Arch Mal Coeur Vaiss 2005;98:236-41.
16. Santos IN, Spadari-Bratfisch RC. Stress and cardiac beta adrenoceptors. Stress 2006;9:69-84. (Pubitemid 44221653)
17. Gauthier C, Leblais V, Kobzik L, et al. The negative intropic effect of beta 3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998;102:1377-84. (Pubitemid 28467566)
18. Sartiani L, De Paoli P, Stillitano F, et al. Functional remodeling in post-myocardial infarcted rats: Focus on beta-adrenoceptor subtypes. J Mol Cell Cardiol 2006;40:258-66. (Pubitemid 43152381)
19. Mery PF, Lohmann SM, Walter U, Fischmeister R. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci 1991;88:1197-201. (Pubitemid 21916192)
20. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
21. 3 adrenoceptor in altered β-adrenergic response in senescent heart: Role of nitric oxide synthase 1-derived nitric oxide. Anesthesiol 2008;109:1045-53.
22. Hoffman BB. Adrenoceptor antagonist drugs. In: Katzung BG, ed. Basic & Clinical Pharmacology. New York: Lange Medical Books/McGraw-Hill, 2001:138-54.
23. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69. (Pubitemid 30080872)
24. Satwani S, Dec GW, Narula J. β-adrenergic blockers in heart failure: Review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Therapeut 2004;9:243-55. (Pubitemid 40130011)
25. Bristow MR, Ginsburg R, Umans V, et al. Beta-1 and beta-2 adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta-1 receptor down-regulation in heart failure. Circ Res 1986;59:297-309. (Pubitemid 17178124)
26. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22:61-71.
27. Dhalla NS, Dixon IMC, Suzuki S, Kaneko M, Kobayashi A, Beamish RE. Changes in adrenergic receptors during the development of heart failure. Mol Cell Biochem 1992;114:91-5.
28. Sethi R, Saini HK, Wang X, Elimban V, Babick A, Dhalla NS. Differential changes in beta-adrenoceptor signal transduction in left and right ventricles of infarcted rats. Can J Physiol Pharmacol 2006;84:747-54. (Pubitemid 44897895)
29. Sethi R, Saini HK, Guo X, Wang X, Elimban V, Dhalla NS. Dependence of changes in beta-adrenoceptor signal transduction on type and stage of cardiac hypertrophy. J Appl Physiol 2007;102:978-84. (Pubitemid 46377021)
30. iα in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990;82:1249-65.
31. Vatner DE, Vatner SF, Fujii AM, Homcy CJ. Loss of high affinity cardiac beta adrenergic receptors in dogs with heart failure. J Clin Invest 1985;76:2259-64. (Pubitemid 16155521)
32. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta-1 adrenergic receptor transgenic mice. Proc Natl Acad Sci 1999;96:7059-64. (Pubitemid 29275009)
33. Iwase M, Bishop SP, Uechi M, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ Res 1996;78:517-24.
34. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta-1 and beta-2 adrenergic receptors on cardiac myocyte apoptosis: Role of pertussis toxin-sensitive G protein. Circulation 1999;100:2210-2.
35. Liggett SB, Teppe NM, Lorenz JN, et al. Early and delayed consequences of beta-2 adrenergic receptor overexpression in mouse hearts: Critical role for expression level. Circulation 2000;101:1707-14. (Pubitemid 30196632)
36. Graham LN, Smith PA, Stoker JB, Mackintosh AF, Mary ASG. Time course of sympathetic neural hyperactivity after uncomplicated myocardial infarction. Circulation 2002;106:793-7.
37. 2+ handling in post-infarction rat heart. Cardiovasc Res 2008;79:42-51.
38. 2+ transport activity by some beta-adrenergic antagonists. Basic Res Cardiol 1984;79:620-6.
39. Dhalla NS, Temsah RM. Sarcoplasmic reticulum and cardiac oxidative stress: An emerging target for heart disease. Expert Opin Ther Targets 2001;5:205-17.
40. Reiken S, Wehrens XHT, Vest JA, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003;107:2459-66. (Pubitemid 36605229)
41. Doi M, Yano M, Kobayashi S, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 2002;105:1374-9. (Pubitemid 34260431)
42. Zou C, Liu ZH, Jiang B, et al. Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:476-9.
43. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY. Effect of beta-blockers on cardiac function and calcium handling in postinfarction heart failure rats. Chest 2005;128:1812-21. (Pubitemid 41324480)
44. 2+ current in rabbit ventricular myocytes. Eur J Pharmacol 1999;376:189-201.
45. i ventricular myocytes compared with those of timolol and atenolol. Circ J 2003;67:83-90.
46. 2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 2007;49:1722-32.
47. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY. Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart. Clin Exp Pharmacol Physiol 2005;32:553-60. (Pubitemid 41021069)
48. 2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun 2005;328:116-24.
49. Esler M. Measurement of sympathetic nervous system activity in heart failure: The role of norepinephrine kinetics. Heart Fail Rev 2000;5:17-25. (Pubitemid 30301508)
50. Zaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MA. Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation 2000;102:344-50. (Pubitemid 30457587)
51. Fu YC, Chi CS, Yin SC, Hwang B, Chiu YT, Hsu SL. Norepinephrine induces apoptosis in neonatal rat endothelial cells via down-regulation of Bcl-2 and activation of beta-adrenergic and caspase-2 pathways. Cardiovasc Res 2004;61:143-51. (Pubitemid 38056690)
52. Machackova J, Sanganalmath SK, Barta J, Dhalla KS, Dhalla NS. Amelioration of cardiac remodeling in congestive heart failure by β-adrenoceptor blockade is associated with depression in sympathetic activity. Cardiovasc Toxicol 2010;10:9-16.
53. Gabrielli O, Puyo AM, De Rosa A, Armando I, Barontini M, Levin G. Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure. Auton Autacoid Pharmacol 2002;22:261-8. (Pubitemid 36969809)
54. Newton GE, Parker JD. Acute effects of beta-1 selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996;94:353-8. (Pubitemid 26266119)
55. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: Differential effects on sympathetic activity. Circulation 2001;104:2194-9. (Pubitemid 33043299)
56. Herman RB, Jesudason PJ, Mustafa AM, Husain R, Choy AM, Lang CC. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol 2003;55:134-8. (Pubitemid 36237859)
57. Majewski H, McCulloch MW, Rand MJ, Story DF. Adrenaline activation of pre-junctional beta-adrenoceptors in guinea-pig atria. Br J Pharmacol 1980;71:435-44. (Pubitemid 11218938)
58. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-4. (Pubitemid 38056032)
59. Xu XL, Zang WJ, Lu J, et al. Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton Neurosci 2006;130:6-16. (Pubitemid 44750853)
60. Machackova J, Sanganalmath SK, Elimban V, Dhalla NS. Beta-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med 2010. (In press)
61. 2+- dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. J Pharmacol Exp Ther 2007;322:222-7.
62. Mak TI, Weglicki WB. Protection by beta-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circulation Res 1988;63:262-6.
63. Kramer JH, Mak T, Freedman AM, Weglicki WB. Propranolol reduces anoxia/reoxygenation-mediated injury of adult myocytes through an anti-radical mechanism. J Mol Cell Cardiol 1991;23:1231-44.
64. Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000;45:788-94. (Pubitemid 30047147)
65. Zhuang XF, Yin CQ, Wang HY, Sun NL. Distinctive effects of carvedilol in the non-infarct zone: Remodeling of the ligated rat heart linked to oxidative stress. J Int Med Res 2009;37:1354-64.
66. Wang R, Miura T, Harada N, et al. Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 2006;318:45-52.
67. Schwarz ER, Kersting PH, Meven DA, et al. Cardioprotection by carvedilol: Antiapoptosis is independent of beta-adrenoceptor blockage in rat heart. J Cardiovasc Pharmacol Ther 2003;3:207-15. (Pubitemid 37158967)
68. Liu N, Yu R, Ruan Y, Zhou Q, Pu J, Li Y. Protective effect of carvedilol on abnormality of L-type calcium current induced by oxygen free radical in cardiomyocytes. J Huazhong Univ Technolog Med Sci 2004;24:433-6. (Pubitemid 41559557)
69. Kametani R, Miura T, Harada N, et al. Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. Circ J 2006;70:321-6.
70. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000;2:277-81. (Pubitemid 30659851)
71. Bartholomeu JB, Rolim NPL, Bechara LRG, et al. Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure. J Mol Cell Cardiol 2008;45:240-9.
72. Kawaki K, Qin F, Shite J, Mao W, Fukuoka S, Liang S. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 2004;287:1003-12.
73. Bohm M, Flesch M, Knorr A, et al. Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res 1998;1:146-55. (Pubitemid 28435439)
74. Fu GS, Huang H, Chen F, et al. Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007;567:223-30. (Pubitemid 46976886)
75. Garlichs CD, Zhang H, Mugge A, Daniel WG. Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur J Clin Invest 1999;29:12-6. (Pubitemid 29084243)
76. Hanada K, Asari K, Saito M, Kawana J, Mita M, Ogata H. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: Effects of carvedilol enantiomers. Eur J Pharmacol 2008;589:194-200.
77. Li Y, Xue Q, Ma J, et al. Effects of imidapril on heterogeneity of action potential and calcium current of ventricular myocytes in infracted rabbits. Acta Pharmacol Sin 2004;25:1458-63. (Pubitemid 39490891)
78. Zhong JH, Chen XP, Yun ML, Li WJ, Chen YF, Yao Z. Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in congestive heart failure. Acta Pharmacol Sin 2007;28:1161-5. (Pubitemid 47197782)
79. Zhang JL, Lu JK, Chen D, et al. Myocardial autophagy variation during acute myocardial infarction in rats: The effects of carvedilol. Chin Med J 2009;122:2372-9.
80. Zhao Q, Wu TG, Jiang ZF, Chen GW, Lin Y, Wang LX. Effect of beta-blockers on beta-3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther 2007;21:85-90. (Pubitemid 46834909)
81. Sabbah HN, Sharov VG, Gupta RC, Todor A, Singh V, Goldstein S. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 2000;36:1698-705.
82. Prabhu SD, Wang G, Luo J, Gu Y, Ping P, Chandrasekar B. Beta-adrenergic receptor blockade modulates Bcl-X(S) expression and reduces apoptosis in failing myocardium. J Mol Cell Cardiol 2003;35:483-93. (Pubitemid 36539454)
83. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of beta-adrenoceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004;110:1083-90. (Pubitemid 39319006)
84. Litwin SE, Katz SE, Morgan JP, Douglas PS. Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. Br J Pharmacol 1999;127:1671-9. (Pubitemid 29369003)
85. Mansuy P, Mougenot N, Ramirez-Gil JF, et al. Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. J Cardiovasc Pharmacol 2000;35:806-13. (Pubitemid 30253624)
86. Gourine A, Bondar SI, Spyer KM, Gourine AV. Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. Circ Res 2008;102:633-6. (Pubitemid 351457859)
87. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-9. (Pubitemid 30233176)
88. Janssen PM, Zeitz O, Rahman A, Hasenfuss G. Protective role of nebivolol in hydroxyl radical induced injury. J Cardiovasc Pharmacol 2001;38:17-23.
89. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25. (Pubitemid 26411746)
90. Doggrell SA. Carvedilol versus other beta-blockers in heart failure. Expert Opin Invest Drugs 2001;10:971-80. (Pubitemid 32421988)
91. Yang Y, Tang Y, Ruan Y, et al. Comparison of metoprolol with low, middle and high doses of carvedilol in prevention of post-infarction left ventricular remodeling in rats. Jpn Heart J 2003;44:979-88. (Pubitemid 41518953)
92. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial infarction collagen postinfarction. J Am Coll Cardiol 2000;36:276-81. (Pubitemid 30466145)
93. 1-blockade attenuates post-infarct remodeling without improvement in myocardial energy metabolism and function in rats with heart failure. Eur J Heart Fail 2003;5:725-32.
94. Zaca V, Rastogi S, Mishra S, et al. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure. Cardiology 2009;112:294-302.
95. Morita H, Suzuki G, Mishima T, et al. Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther 2002;16:443-9. (Pubitemid 36255744)
96. Terrovitis JV, Anastasiou-Nana MI, Nanas JN. Out-patient management of chronic heart failure. Expert Opin Pharmacother 2005;6:1857-81. (Pubitemid 41358424)
97. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34. (Pubitemid 27357123)
98. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trial. Circulation 1998;98:1184-91.
99. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550-60.
100. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
101. MERIT-HF Study Group. Effects of controlled-release metoprolol on mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2008;283:1295-302.
102. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): Randomized controlled trial. Lancet 2003;362:7-13. (Pubitemid 36835815)
103. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996;334:1349-55. (Pubitemid 26152713)
104. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001;357:1385-90.
105. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. J Am Coll Cardiol 2004;43:1423-9.
106. Celic V, Pencic B, Dekleva M, Dimkovic S, Kocijancic M. Metoprolol and atenolol in mild-to-moderate chronic heart failure: Comparative study. Srp Arh Celok Lek 2005;133:242-7.
107. CIBIS-II group. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial. Lancet 1999;353:9-13.
108. Flather MD, Shibata MC, Coats AJ, et al. Randomization trial to determine the effect of nebivolol on mortality and cardiovascular hospital admissions in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. (Pubitemid 40222359)
109. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207-9. (Pubitemid 27329224)
110. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of beta-adrenergic antagonists (Atenolol, Metoprolol tartrate, Carvedilol) on risk of rehospitalization in adults with heart failure. Am J Cardiol 2007;100:690-6. (Pubitemid 47225169)
111. Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: A subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003;24:552-9. (Pubitemid 36343101)
112. Dobre D, van Veldhuisen DJ, Goulder MA, Krum H, Willenheimer R. Clinical effects of initial six months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III trial. Cardiovasc Drugs Ther 2008;22:399-405.
113. Ritter JM. Nebivolol: Endothelium-mediating vasodilating effect. J Cardiovasc Pharmacol 2001;38:13-6.
114. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007;50:652-6. (Pubitemid 47442727)